RECHARGE Sub-Study to the Implantable Systems Performance Registry (ISPR)

Recruitment & Eligibility

Inclusion Criteria

Patient is enrolled in the Implantable Systems Performance Registry (ISPR) and will receive one Activa RC as their first implantable neurostimulator or as a replacement implantable neurostimulator for DBS.
Patient must meet the indications in the Activa RC labeling.
Patient (or patient's legally authorized representative) signs and dates the appropriate RECHARGE Informed Consent Form and/or Informed Assent Form and Authorization to Use and Disclose Health Information (HIPAA, US only).
Patient has a diagnosis of Parkinson's Disease, Essential Tremor, or dystonia that meets the approved indication for Activa RC in the applicable geography.
Patient with dystonia is 7 years of age or older (EU only).
Patient with either PD or ET is 18 years of age or older.
Patient (or caregiver) is able to use the patient programmer and correctly interpret the icons.
Patient (or caregiver) is able and willing to regularly monitor the status of the rechargeable battery and respond appropriately.
Patient (or caregiver) is able to locate the INS, position the recharge antenna for sufficient coupling, put on the recharge holster/belt, and monitor progress during the recharge session.
Patient (or caregiver) is able to perform recharging activities for sufficient duration and frequency to maintain therapy and to perform recharging activities on an ongoing basis.
Patient is willing and able to comply with protocol requirements.

Exclusion Criteria

Patient has a contraindication identified in the Activa RC labeling.
Patient who is currently enrolled in or plans to enroll in any concurrent drug and/or device study that may confound the results of the RECHARGE study.
Patient has or will be implanted with a non-Medtronic Deep Brain Stimulation system component.

Arm && Interventions

Group	Intervention	Description
Patients receiving an Activa RC implant	Activa RC	-

Primary Outcome Measures

Name	Time	Method
Identify the Rate of User-related Battery Depletion Adverse Events Per Subject-month Requiring Intervention by a Health Care Professional (HCP) and/or the HCP's Designee, Within the First 3 Months of the Activa RC System Being Turned ON.	3 months	Subject-months of follow-up were defined as the time from device activation to the earlier of a subject's 3-month visit or until the subject exited from the study. Any user-related battery depletion adverse events requiring intervention by a health care professional (HCP) and/or the HCP's designee were collected. The event rate per 100 subject-months of follow-up is defined as the number of user-related battery depletion events divided by the total subject follow-up months through the 3-month visit, all multiplied by 100.

Secondary Outcome Measures